Compare ARK Genomic Revolution ETF (ARKG) vs ARK Space & Defense Innovation ETF (ARKX) Price & Performance

ARKG trades at $44.49, up 0.41% today, with a bullish technical bias from moving averages but overbought RSI signals. The ETF focuses on genomic revolution stocks, with top 10 holdings comprising 59% of assets and a long-term EPS growth rate of 10.7% (Seeking Alpha, 2026-07-28). Recent news highlights biotech sector strength driven by FDA friendliness and AI-driven drug discovery.

Outlook is cautiously optimistic given sector tailwinds, but high concentration and volatility pose risks. The ETF's exposure to small- and mid-cap biotech offers growth potential, yet investors face regulatory and market sentiment shifts. Near-term performance may hinge on broader tech trends and biotech M&A activity.

ARK Space & Defense Innovation ETF (ARKX) trades at $34.8, up 1.13% today, with a bullish technical signal driven by strong moving average alignment. The ETF focuses on space economy exposure, including holdings like SpaceX (8.31%) and Rocket Lab (6.27%), benefiting from growing commercial and defense space investments. Recent news highlights competition with other space ETFs and the impact of SpaceX's IPO on the sector.

Outlook remains positive due to thematic tailwinds in space innovation, but high volatility and stretched valuations in key holdings pose risks. Investors gain diversified access to a high-growth theme, though expense ratios and sector concentration require careful consideration amid market fluctuations.